evitria AG, the market-leading transient CHO expression service provider, today announces the closing of a license agreement with mAbsolve Ltd for mAbsolve’s proprietary STR technology. Under the agreement, evitria will supply their global client base with antibodies bearing STR silencing modifications. These clients will then be able to evaluate the STR technology in their experiments without securing additional R&D licenses, but benefit from technical support and commercial term certainty provided by the mAbsolve team.
“We are excited to add the STR technology into our antibody engineering and modification capabilities” says evitria’s Chief Executive Officer, Christian Eberle. “STR has been shown to outperform all other modifications for generating truly silent Fc-domains, and fits perfectly with our best-in-class approach at evitria.”
“We cannot wait to get STR into the hands of more researchers” says mAbsolve’s Chief Executive Officer, Geoff Hale. “evitria’s focus on high quality CHO expression means that it is perfectly positioned to offer our technology to the therapeutic market, and we look forward to supporting their client’s with this technolgy.”
evitria AG is the market-leading transient CHO expression service provider. Based in Zurich, Switzerland, they have supported a global base of preclinical researchers with CHO-based transient expression for over 12 years. With a track record of more than 90,000 transfections and more than 15,000 antibodies and proteins purified, evitria has fully optimised their workflows for high quality productions in the shortest timeframes possible.
mAbsolve have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs. They are building partnerships with Universities, Biotech and Pharma companies to make this new technology widely available.